Hematologic Oncology

Navtemadlin yields improvements in symptom score reductions ad spleen volume reduction among patients with relapsed/refractory myelofibrosis.

NFKB1 rs230511 genetic variant improves treatment outcomes for patients with polycythemia vera and essential thrombocythemia.

Atrial fibrillation occur at a smaller likelihood with second-generation BTK inhibitors vs first-generation BTK inhibitors in B-cell hematologic cancers.

Navtemadlin shows influence in myelofibrosis hallmarks such as CD34-positive cell proliferation and pro-inflammatory cytokines in the phase 3 BOREAS trial.

CancerNetwork co-hosts Kristie L. Kahl and Andrew Svonavec highlight abstracts to look out for surrounding the multidisciplinary approach at the upcoming ASH Annual Meeting in San Diego, with some additional tidbits to round out the main event.

Findings from the Phase 3 AURIGA trial support the use of lenalidomide plus daratumumab vs lenalidomide alone as post-transplant maintenance therapy for patients with newly diagnosed multiple myeloma.

David M. Swoboda, MD, and Andrew Kuykendall, MD, spoke about the current treatment strategies and potential advancements that may improve outcomes such as spleen volume reduction in the myelofibrosis field.

Hematologic cell transplantation use rates have improved, although they still show disparities for minority groups such as non-Hispanic Black populations.

Posttransplant cyclophosphamide leads to unique changes in vascular biomarkers, revealing a distinct toxicity profile compared to other GVHD prophylaxis regimens.

These findings demonstrate the potential risks associated with CNI-based immunosuppression in stem cell transplantation without concurrent strategies to eliminate alloreactive T cells.

Data from the IMerge trial affirm the enduring responses and clinical benefit with imetelstat in those with transfusion-dependent MDS.

Data from the PERSEUS trial support the benefit of D-VRd and DR maintenance as a standard of care in transplant-eligible newly diagnosed multiple myeloma.

A ready-to-use subcutaneous or intravenous injection of bortezomib for multiple myeloma and MCL has been approved by the FDA.

A recent study investigated the incidence and clinical outcomes of acute graft-versus-host disease following post-transplantation cyclophosphamide-based prophylaxis in hematopoietic cell transplantation.

The Best of CAR T at the 2024 Tandem Meetings Webinar Series, which aired on June 27, 2024, aimed to provide a comprehensive overview of the latest advancements and research in CAR T cell therapy.

A watch-and-wait method was implemented when vitamin D was given prior to treatment for chronic lymphocytic leukemia.

Results from the phase 2 AGAVE-201 trial of axatilimab for patients with relapsed/refractory chronic GVHD support the FDA approval.

A recent study, published in Blood Advances, has identified that pre-HSCT conditioning induces the extracellular release of damaged mitochondria, exacerbating GVHD.

A recent study, published in Cell, has identified the circadian rhythm of TILs as a key determinant in the efficacy of immunotherapy treatments such as CAR T-cell therapy and immune checkpoint blockade.

Cyclophosphamide-based prophylaxis for GVHD showed similar outcomes across racial subgroups regardless of matched or mismatched unrelated donors.

Mismatched unrelated donor consideration may expand donor numbers, especially for those with minority ancestry seeking hematopoietic cell transplantation.

Following rare CRS and ICANS incidence following CAR T-cell therapy, investigators propose a reduced 2-week monitoring period with extensions as needed.

After allogeneic hematopoietic cell transplantation, pregnancies could be carried out and were successful.

Researchers at the Mayo Clinic have found that mesenchymal stromal cells engineered with chimeric antigen receptors can enhance immunosuppression in the context of immune-related disorders.

In a collaborative effort between 18 centers, researchers have developed a system that effectively stratifies children at the onset of acute graft versus host disease for risk of non-relapse mortality over 6 months.

Frontline acalabrutinib plus bendamustine/rituximab may become a new standard therapy in MCL, according to Michael Wang, MD.

Approved for use in newly diagnosed and previously treated myelofibrosis, momelotinib may addresses key manifestations of the disease.

Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.

Phase 1 data show no dose-limiting toxicities with sonrotoclax plus zanubrutinib for patients with relapsed/refractory CLL or SLL.

Data from the phase 3b JUMP trial support the use of ruxolitinib in myelofibrosis regardless of baseline or treatment-related anemia.